Activated protein C variants with normal cytoprotective but reduced anticoagulant activity

Laurent O. Mosnier, Andrew J. Gale, Subramanian Yegneswaran, and John H. Griffin

Recombinant activated protein C (APC), a well-defined anticoagulant enzyme, reduced mortality in severe sepsis patients in a phase 3 trial. However, 2 potent anticoagulants, antithrombin III and recombinant tissue factor pathway inhibitor, failed to do so, implying the physiologic relevance of APC’s less well-defined direct anti-inflammatory and antiapoptotic activities. Recombinant APC therapy conveys an increased risk of serious bleeding complications due to APC anticoagulant activity. To generate recombinant APC variants with reduced risk of bleeding due to reduced anticoagulant activity, we dissected APC’s anticoagulant activity from its cytoprotective activity by site-directed mutagenesis. Using stauroporine-induced endothelial cell apoptosis assays, we show here that Ala mutations (RR229/230AA and KKK191_193AAA) in 2 APC surface loops that severely reduce anticoagulant activity result in 2 APC variants that retain normal antiapoptotic activity that requires protease activated receptor-1 and endothelial cell protein C receptor. Thus, it is possible to reduce anticoagulant activity while preserving antiapoptotic activity of recombinant APC variants. We suggest that therapeutic use of such APC variants may reduce serious bleeding risks while providing the beneficial effects of APC acting directly on cells. (Blood. 2004;104:1740-1744)

© 2004 by The American Society of Hematology

Materials and methods

Materials

Human α-thrombin was purchased from Enzyme Research Laboratories (South Bend, IN). Normal human citrate-anticoagulated plasma was from...
George King Bio-Medical (Overland Park, KS). The chromogenic substrate 1-pyroglutamyl-t-prolyl-t-arginine-p-nitroanilide hydrochloride (S-2366) was obtained from Chromogenix (Franklin, OH).

Preparation of recombinant activated protein C

Mutant protein C expression vectors were constructed, and recombinant protein C mutants were purified from conditioned media as described. Purified protein C was activated by thrombin. Briefly, protein C in HBS (50 mM HEPES [N-2-hydroxyethylpiperezine-N'-2-ethanesulfonic acid], 150 mM NaCl) with 2 mM EDTA (ethylenediaminetetraacetic acid) and 0.5% bovine serum albumin (BSA), pH 7.4, at a concentration of 600 μg/mL was incubated for 2.5 hours with 12 μg/mL thrombin at 37°C followed by the addition of 1.1 units of hirudin per unit of thrombin to inactivate the thrombin. Subsequently, thrombin was removed by anion-exchange chromatography with NaCl gradient elution. Residual thrombin, as determined by fibrin clotting, accounted for less than 0.00025% (moles of thrombin per moles of APC) of the protein. Concentrations of recombinant wild-type (rwt) APC and APC mutants were determined by active-site titration adapted from Chase and Shaw using APC at about 8 moles of thrombin per moles of protein. Concentrations of fibrin, as determined by g/mL of staurosporine-treated (2 g/mL) EA.hy926 endothelial cells. Blocking antibodies against PAR-1 (WEDE-15 fluorescence microscope (20× objective, 0.4 NA) fitted with a Spot RT digital color camera (Diagnostic Instruments, Sterling Heights, MI). Dako fluorescent mounting medium (Dako, Carpinteria, CA) was used. Images were prepared for presentation using Adobe Photoshop.

PAR-1 peptide cleavage

The interactions of rwt APC and APC variants (500 nM) with PAR-1 N-terminal tail peptide (TR33-62) were studied using a synthetic peptide representing PAR-1 residues 33-62 (Bio Synthesis, Lewisville, TX). The peptide sequence was Arg229/230-APC and 3K3A-APC, and these were cleaved by APC between Arg41 and Ser42. The substrate peptide and the 2 peptide products of thrombin or APC cleavage at Arg41 (TR33-41 and TR42-62) were resolved and analyzed by high-performance liquid chromatography (HPLC) and quantitated essentially as described. All TR33-62 cleavage experiments with APC contained 5 nM hirudin to assure that the observed cleavage was not due to thrombin contamination.

Results

APC variants with reduced anticoagulant activity but normal antiapoptotic activity

Available information indicates that APC’s direct cytoprotective action on cells requires EPCR and PAR-1. EPCR on the endothelial surface binds to the Gla domain of APC, and this is assumed to position APC’s active site proximate to the PAR-1 activating cleavage site at Arg41. Cleavage of PAR-1 at Arg41 by APC presumably initiates anti-inflammatory and antiapoptotic reactions. We sought to identify APC variants with reduced anticoagulant activity but with normal cytoprotective activity. Following initial screening of various APC protease domain variants with low anticoagulant activity (data not shown), we decided to study in detail 2 APC variants, designated 229/230-APC (Arg229Ala and Arg230Ala in the Cu²⁺-binding loop) and 3K3A-APC (Lys191Ala, Lys192Ala, and Lys193Ala in loop 37). The antiapoptotic, anticoagulant, and amidolytic activities of 229/230-APC and 3K3A-APC were determined and compared with the activities of recombinant wild-type (rwt) APC and of a hydrolytically inactive mutant, S360A-APC, containing Ala in place of the active site residue, Ser360. The 2 APC protease domain loop variants, 229/230-APC and 3K3A-APC, had the same enzymatic activity against a small chromogenic substrate, S-2366, as rwt APC (Figure 1A), indicating the structural and functional preservation of the APC active site, whereas these variants had markedly decreased anticoagulant activity (Figure 1B) that was due to impaired cleavage at Arg506 in factor V a (Table 1). Although S360A-APC had no chromogenic activity (Figure 1A), the anticoagulant activity of S360A-APC was about 23% in the conditions of the APTT assay (Figure 1B). As previously described, in contrast to...
normal rwt APC, this anticoagulant activity is independent of the incubation time of APC with plasma and appears to involve binding of APC exosites to factor Va such that there is inhibition of factor Xa and prothrombin binding to factor Va.

To determine cytoprotective activity of these APC variants, staurosporine-induced endothelial cell apoptosis was studied. APC-mediated inhibition of staurosporine-induced apoptosis is time dependent and dose dependent, and it requires APC’s active site, PAR-1, and EPCR. Half-maximum inhibition of staurosporine-induced apoptosis by rwt APC was achieved at 0.16 nM under the conditions employed (Figure 2A). Dose-dependent inhibition of apoptosis by 229/230-APC and 3K3A-APC was indistinguishable from that of rwt APC with half-maximum inhibition at 0.17 nM and 0.14 nM, respectively (Figure 2A). No inhibition of apoptosis by an APC mutant lacking the active site serine, S360A-APC, was observed (Figure 2A-C). The ability of rwt APC and APC variants to inhibit generation of activated caspase-3 in endothelial cells exposed to staurosporine was monitored immunohistochemically. Recombinant wild-type APC and the variants, 229/230-APC and 3K3A-APC, each similarly reduced activated caspase-3–positive cells by approximately 70%, whereas the active site mutant, S360A-APC, had no effect (Figure 2B-C).

Thus, certain protease domain residues essential for normal anticoagulant activity of APC—namely, Arg229, Arg230, Lys191, Lys192, and Lys193—are not required for normal antiapoptotic activity of APC.

APC antiapoptotic effects require PAR-1 and EPCR. Similarly, the antiapoptotic activity of 229/230-APC and 3K3A-APC in assays of staurosporine-induced endothelial cell apoptosis required PAR-1 and EPCR because the cytoprotective activity of each APC variant was inhibited by 72% and 69% in the presence of antibodies against EPCR that block binding of APC to the receptor and by 88% and 55% in the presence of blocking anti–PAR-1 antibodies, respectively (Figure 3). These results indicate that interactions between cells and the 2 APC variants, like rwt APC, require PAR-1 and EPCR.

Table 1. Recombinant wild-type and mutant APC activities

<table>
<thead>
<tr>
<th>Mutant</th>
<th>APC sequence</th>
<th>Cytoprotective activity, % rwt APC*</th>
<th>Anticoagulant activity, % rwt APC†</th>
<th>Cytoprotective to anticoagulant ratio‡</th>
<th>Factor Va inactivation cleavage at Arg506 (Arg306), % rwt APC§</th>
<th>Amidolytic activity, % rwt APC∥</th>
<th>PAR-1 peptide TR33-62 cleavage, % rwt APC¶</th>
</tr>
</thead>
<tbody>
<tr>
<td>rwt APC#</td>
<td>None</td>
<td>100</td>
<td>100</td>
<td>1.0</td>
<td>100 (100)</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>229/230-APC</td>
<td>227-DBBWE-232</td>
<td>94</td>
<td>13</td>
<td>7.2</td>
<td>25 (110)</td>
<td>102</td>
<td>116</td>
</tr>
<tr>
<td>3K3A-APC</td>
<td>189-DSDKKLA-195</td>
<td>114</td>
<td>4.6</td>
<td>25</td>
<td>11 (67)</td>
<td>109</td>
<td>88</td>
</tr>
<tr>
<td>S360A-APC</td>
<td>358-GDGG-362</td>
<td>&lt;1**</td>
<td>23††</td>
<td>0</td>
<td>&lt;1*** (&lt;1***)</td>
<td>&lt;1**</td>
<td>&lt;3**</td>
</tr>
</tbody>
</table>

For the APC sequences, mutations to Ala are indicated in boldface underlined text.

*Derived from the concentrations of APC required for half-maximal inhibition of the staurosporine-induced apoptosis (Figure 2A).
†Based on the APTT dose-response data determined for rwt APC and APC variants (0.5-32 nM) (Figure 1B).
‡Derived from the ratio of relative activities for cytoprotective and anticoagulant activities given in the previous 2 columns.
§Based on apparent second-order rate constants determined previously.17,22
∥Derived from the ratio of relative activities for cytoprotective and anticoagulant activities given in the previous 2 columns.
¶Based on the catalytic efficiency derived from Figure 4 for cleavage of the PAR-1 peptide (TR33-62) by rwt APC and APC variants (500 nM).
#Recombinant wild-type APC (rwt APC) activity was defined as 100%, and values for mutant APC are given as percentage of rwt APC activity.
**No detectable activity under the conditions of the assay.
††Anticoagulant activity of S360A-APC is not due to proteolysis of factor Va and, in contrast to rwt APC, is independent of the incubation time of APC with the plasma.22

For personal use only.
at least 3 independent experiments.

Apoptosis was analyzed by the uptake of Annexin V and expressed as a percentage relative to the percentage of apoptotic cells observed in the absence of APC. Cells were incubated with rwt APC or APC variants for 5 hours prior to induction of apoptosis by staurosporine (10 μM, 1 hour). Apoptosis was analyzed by the uptake of Annexin V and expressed as a percentage relative to the percentage of apoptotic cells observed in the absence of added APC (20% of all cells), which was set as 100%. Each bar represents relative apoptosis in the absence of APC and staurosporine. Each bar represents the mean ± SEM from at least 3 independent experiments.

Cleavage of synthetic PAR-1 N-terminal tail by wild-type and variant APC

The absence of antiapoptotic activity of S360A-APC and the requirement for PAR-1 imply that a primary mechanistic step for APC’s anticoagulant activity involves PAR-1 proteolytic activation. To characterize the effects of the mutations in APC on proteolytic activation of PAR-1 due to cleavage at Arg41, a synthetic 30-mer peptide representing the PAR-1 N-terminal sequence (residues 33-62 [TR33-62]) was studied as an APC substrate. This TR33-62 PAR-1 peptide is cleaved at Arg41 by thrombin. APC cleaves another PAR-1 synthetic N-terminal peptide at Arg41, the thrombin cleavage site. Using HPLC, quantitative analysis was found that rwt APC cleaved the TR33-62 peptide at Arg41 and generated similar fragments as thrombin, TR33-41, and TR42-62 but at approximately a 25 000-fold lower catalytic efficiency based on comparison of kcat/Km for the 2 enzymes (data not shown). When the time course for TR33-62 cleavage was monitored using HPLC to quantify the disappearance of the peak for the TR33-62 substrate and the appearance of the TR42-62 product, the results showed that there were no substantial differences in the rate of TR33-62 cleavage between the rwt APC, 229/230-APC, and 3K3A-APC (Figure 3). Similarly, no significant differences in APC-induced Ca"++-intracellular flux monitored as FURA-2 AM fluorescence changes were observed in EA.hy926 endothelial cells when rwt APC was compared with the 2 antiapoptotic APC variants, 229/230-APC and 3K3A-APC (data not shown). These results are consistent with the hypothesis that APC cleaves PAR-1 at Arg41 and that the mutations in the 2 APC variants described here with reduced antiapoptotic activity but with normal antiapoptotic activity did not significantly reduce the ability of the protease domain of APC to cleave PAR-1 at Arg41.

Discussion

In vivo data suggested there might be an important distinction between the anticoagulant and cell protective activities of APC. APC-induced neuroprotective effects in a murine ischemic stroke model were observed at low APC doses that had no effect on fibrin deposition or on restoration of blood flow, indicating that APC’s neuroprotective effects, at least in part, were independent of APC’s antiapoptotic activity. Moreover, APC provides direct protection for neurons against NMDA-induced excitotoxic injury. Interestingly, heterozygosity for the Arg506Gln mutation in factor V (factor VLeiden), which effectively retards factor Va inactivation by APC and is a significant risk factor for venous thrombosis, is reported to protect against lipopolysaccharide (LPS)–induced sepsis in mice and may also do the same in humans. This implies that inactivation of factor Va, the hallmark of APC anticoagulant activity, may not provide the entire explanation for APC-mediated reduction of mortality in patients with severe sepsis.

To generate recombinant APC variants with reduced risk of bleeding due to reduced antiapoptotic activity, we dissected APC’s anticoagulant activity from its cytotoxic activity by site-directed mutagenesis. Using staurosporine-induced endothelial cell apoptosis assays, we show here that Ala mutations (RR229/230AA and KKK191_193AAA) in 2 APC surface loops that severely reduce antiapoptotic activity result in 2 APC variants that retain normal antiapoptotic activity that requires PAR-1 and EPCR. Moreover, these 2 APC variants retain a normal ability to cleave a PAR-1 N-terminal peptide at Arg41. To compare these 2 APC variants with rwt APC in terms of their relative antiapoptotic and anticoagulant activities, we assigned the observed activity of rwt APC a value of 100% and calculated the percent activity of each APC variant from dose–response data (Figures 1 and 2). This normalization inherently yields a “cytotoxic to anticoagulant” ratio for rwt APC of 1.0 (Table 1). When the ratio of antiapoptotic activity to anticoagulant activity was calculated for the APC mutants (Table 1), the 2 APC variants exhibited 7 times and 25 times greater antiapoptotic activity relative to anticoagulant activity compared with rwt APC, respectively.

Thus, these data imply that the RR229/230AA and KKK191_193AAA mutations in APC, which cause decreased cleavage at Arg506 in factor Va, do not impair cleavage at Arg41 in PAR-1.

The most notable serious adverse event associated with APC treatment of severe sepsis patients is serious bleeding. Administration of APC in the Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial was associated with an increase in serious bleeding events, most of which occurred during the 4-day APC infusion period (2.1% [20 of 940] versus 0.7% [6 of 881]; APC versus placebo; P < .01). Although APC reduced mortality in severe sepsis, at least some of APC’s lifesaving effects may have been counteracted by an increase in hemorrhage as cause of death.

![Figure 3. Inhibition of apoptosis by rwt APC and APC variants requires PAR-1 and EPCR.](image)

![Figure 4. Cleavage of PAR-1 N-terminal TR33-62 peptide at Arg41 by rwt APC and APC variants.](image)
In summary, here we provide 2 examples of APC mutants—namely, 3K3A-APC and 229/230-APC—that have a substantial reduction in anticoagulant activity but retain normal antiapoptotic activity. These findings indicate that genetic engineering strategies aimed at reducing APC’s anticoagulant activity while preserving EPCR-dependent ability of APC to signal cells via PAR-1 activation are feasible. We suggest that therapeutic use of such APC variants are likely to reduce serious bleeding events associated with clinical use of rwt APC while providing the beneficial effects of APC acting directly on cells.

Acknowledgments

We thank Dr L. Brass (University of Pennsylvania, Philadelphia, PA) for PAR-1 antibodies, Dr C. J. S. Edgell (University of North Carolina, Chapel Hill) for the EA.hy926 endothelial cell line, and Ms Xiao Xu for expert technical assistance.

References

Activated protein C variants with normal cytoprotective but reduced anticoagulant activity

Laurent O. Mosnier, Andrew J. Gale, Subramanian Yegneswaran and John H. Griffin